Management of acute loss of asthma control: yellow zone strategies.


Journal

Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359

Informations de publication

Date de publication:
04 2019
Historique:
pubmed: 17 1 2019
medline: 17 3 2020
entrez: 17 1 2019
Statut: ppublish

Résumé

Asthma exacerbations are associated with a significant burden to both the individual patient and to the healthcare system. Patients often step-up home therapies in response to increased asthma symptoms, and the asthma action plan was created to empower patients to self-manage their asthma care. The yellow (intermediate) zone of the asthma action plan is frequently poorly defined, and current Expert Panel Report 3 guideline recommendations are not effective for all patients. This article reviews the evidence behind various recommended yellow zone intervention strategies. There are many potential methods of delivering yellow zone therapy, and recent studies have assessed preventive efficacy of a scheduled increase in controller medication(s), reliever medication(s), or a symptom-driven combination of both. The literature suggests that, in certain asthma subpopulations, some methods may be more efficacious than others. Multiple yellow zone approaches may be beneficial, and the yellow zone is not a 'one size fits all' narrative.

Identifiants

pubmed: 30649012
doi: 10.1097/ACI.0000000000000512
doi:

Substances chimiques

Anti-Asthmatic Agents 0
Drug Combinations 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

154-160

Auteurs

Brooke I Polk (BI)

Allergy and Immunology, Washington University in St. Louis, St. Louis, Missouri.

Chitra Dinakar (C)

Allergy, Immunology, and Pulmonary Medicine, Stanford University, Palo Alto, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH